Aarti Drugs Limited — Others, 14-02-2025: Action(s) taken or orders passed

Aarti Drugs Limited has confirmed that it has been removed from the US FDA's Import Alert 66-40, allowing it to resume exports to the US market, including key products like Ciprofloxacin HCl API and Zolpidem Tartrate API. This regulatory clearance enhances the company’s operational capacity and opens up significant market opportunities in the US, potentially boosting revenues. While there are currently no reported financial impacts, this development could positively influence investor sentiment by signaling strengthened compliance and operational readiness. Overall, this news points to a positive outlook for the company as it can now compete more effectively in the US pharmaceutical market.